PF-05212384 (PKI-587)PI3Kα, PI3Kγ and mTOR inhibitor CAS# 1197160-78-3 |
- LX-4211
Catalog No.:BCC1714
CAS No.:1018899-04-1
- Dapagliflozin
Catalog No.:BCC2552
CAS No.:461432-26-8
- Canagliflozin
Catalog No.:BCC3696
CAS No.:842133-18-0
- Empagliflozin (BI 10773)
Catalog No.:BCC2472
CAS No.:864070-44-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1197160-78-3 | SDF | Download SDF |
PubChem ID | 44516953 | Appearance | Powder |
Formula | C32H41N9O4 | M.Wt | 615.73 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | PKI-587 | ||
Solubility | DMSO : 4 mg/mL (6.50 mM; Need warming) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea | ||
SMILES | CN(C)C1CCN(CC1)C(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5CCOCC5)N6CCOCC6 | ||
Standard InChIKey | DWZAEMINVBZMHQ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent and selective dual inhibitor of PI 3-kinase/mTOR (IC50 values are 0.4, 1.6 and 5.4 nM for PI 3-Kα, mTOR and PI 3-Kγ respectively). Exhibits selectivity over 234 other protein kinases (IC50 >10 μM). Potently inhibits tumor cell growth in 37 different tumor cell lines (IC50 < 100 nM). Also exhibits antitumor activity in MDA-361, HCT-116, H1975 and U87MG xenograft models. |
PF-05212384 (PKI-587) Dilution Calculator
PF-05212384 (PKI-587) Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.6241 mL | 8.1204 mL | 16.2409 mL | 32.4818 mL | 40.6022 mL |
5 mM | 0.3248 mL | 1.6241 mL | 3.2482 mL | 6.4964 mL | 8.1204 mL |
10 mM | 0.1624 mL | 0.812 mL | 1.6241 mL | 3.2482 mL | 4.0602 mL |
50 mM | 0.0325 mL | 0.1624 mL | 0.3248 mL | 0.6496 mL | 0.812 mL |
100 mM | 0.0162 mL | 0.0812 mL | 0.1624 mL | 0.3248 mL | 0.406 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
PF-05212384 is an inhibitor of PI3K/mTOR with IC50 values of 0.4nM, 6nM, 8nM, 6nM and 1.4nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and mTOR, respectively [1].
PF-05212384 is a pan-PI3K/mTORinhibitor and shows to be highly selective for PI3K and mTOR. Besides the wt P13K, PF-05212384 can also inhibit mutant P13K with IC50 values of 0.6nM for both H1047R and E545K mutants. In cellular assay, PF-05212384 potently inhibits tumor growth in MDA-361 and PC3-MM2 cell lines with IC50 values of 4nM and 13.1nM, respectively. Meanwhile, PF-05212384 suppresses the phosphorylation of PI3K/mTOR signaling pathway proteins in cells. It inhibits the phosphorylation of Akt as well as the Akt effector proteins including GSK3 kinase, ENOS and PRAS 40. Moreover, PF-05212384 has potent anti-tumor activity in a variety of xenograft models including H1975, BT474, HCT116, H1975 and U87MG [1, 2]
References:
[1] Venkatesan A M, Dehnhardt C M, Delos Santos E, et al. Bis (morpholino-1, 3, 5-triazine) derivatives: potent adenosine 5′-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. Journal of medicinal chemistry, 2010, 53(6): 2636-2645.
[2] Mallon R, Feldberg L R, Lucas J, et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clinical Cancer Research, 2011, 17(10): 3193-3203.
- 5-Methylfurmethiodide
Catalog No.:BCC6707
CAS No.:1197-60-0
- 4-Aminophenylacetic acid
Catalog No.:BCC8687
CAS No.:1197-55-3
- Tranexamic acid
Catalog No.:BCN2710
CAS No.:1197-18-8
- 3',4'-Dihydroxyacetophenone
Catalog No.:BCN4775
CAS No.:1197-09-7
- Amadacycline methanesulfonate
Catalog No.:BCC1356
CAS No.:1196800-40-4
- Yucalexin P-17
Catalog No.:BCN6595
CAS No.:119642-82-9
- Moguisteine
Catalog No.:BCC4925
CAS No.:119637-67-1
- Naloxone benzoylhydrazone
Catalog No.:BCC5757
CAS No.:119630-94-3
- Arecaidine but-2-ynyl ester tosylate
Catalog No.:BCC6627
CAS No.:119630-77-2
- Sulfo-NHS-Biotin
Catalog No.:BCC3576
CAS No.:119616-38-5
- Olprinone Hydrochloride
Catalog No.:BCC1821
CAS No.:119615-63-3
- PF-3845
Catalog No.:BCC2326
CAS No.:1196109-52-0
- Sutchuenmedin A
Catalog No.:BCN6854
CAS No.:1197194-31-2
- UNC 0224
Catalog No.:BCC2430
CAS No.:1197196-48-7
- 2-Epitormentic acid
Catalog No.:BCN6084
CAS No.:119725-19-8
- Fupenzic acid
Catalog No.:BCN6085
CAS No.:119725-20-1
- Baohuoside VII
Catalog No.:BCN2889
CAS No.:119730-89-1
- TGR5 Receptor Agonist
Catalog No.:BCC4195
CAS No.:1197300-24-5
- Sazetidine A dihydrochloride
Catalog No.:BCC7468
CAS No.:1197329-42-2
- SDZ 205-557 hydrochloride
Catalog No.:BCC7246
CAS No.:1197334-02-3
- SB 206553 hydrochloride
Catalog No.:BCC7143
CAS No.:1197334-04-5
- Schizanthine G
Catalog No.:BCN1938
CAS No.:119736-74-2
- Schizanthine M
Catalog No.:BCN1939
CAS No.:119736-78-6
- Tautomycetin
Catalog No.:BCC7320
CAS No.:119757-73-2
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.[Pubmed:25652454]
Clin Cancer Res. 2015 Apr 15;21(8):1888-95.
PURPOSE: To evaluate safety (primary endpoint), tolerability, pharmacokinetics, pharmacodynamic profile, and preliminary activity of the intravenous, pan-class I isoform PI3K/mTOR inhibitor PF-05212384 in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Part 1 of this open-label phase I study was designed to estimate the maximum-tolerated dose (MTD) in patients with nonselected solid tumors, using a modified continual reassessment method to guide dose escalation. Objectives of part 2 were MTD confirmation and assessment of preliminary activity in patients with selected tumor types and PI3K pathway dysregulation. RESULTS: Seventy-seven of the 78 enrolled patients received treatment. The MTD for PF-05212384, administered intravenously once weekly, was estimated to be 154 mg. The most common treatment-related adverse events (AE) were mucosal inflammation/stomatitis (58.4%), nausea (42.9%), hyperglycemia (26%), decreased appetite (24.7%), fatigue (24.7%), and vomiting (24.7%). The majority of patients treated at the MTD experienced only grade 1 treatment-related AEs. Grade 3 treatment-related AEs occurred in 23.8% of patients at the MTD. No treatment-related grade 4-5 AEs were reported at any dose level. Antitumor activity was noted in this heavily pretreated patient population, with two partial responses (PR) and an unconfirmed PR. Eight patients had long-lasting stable disease (>6 months). Pharmacokinetic analyses showed a biphasic concentration-time profile for PF-05212384 (half-life, 30-37 hours after multiple dosing). PF-05212384 inhibited downstream effectors of the PI3K pathway in paired tumor biopsies. CONCLUSIONS: These findings demonstrate the manageable safety profile and antitumor activity of the PI3K/mTOR inhibitor PF-05212384, supporting further clinical development for patients with advanced solid malignancies.
Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.[Pubmed:21325073]
Clin Cancer Res. 2011 May 15;17(10):3193-203.
PURPOSE: The aim of this study was to show preclinical efficacy and clinical development potential of PKI-587, a dual phosphoinositide 3-kinase (PI3K)/mTOR inhibitor. EXPERIMENTAL DESIGN: In vitro class 1 PI3K enzyme and human tumor cell growth inhibition assays and in vivo five tumor xenograft models were used to show efficacy. RESULTS: In vitro, PKI-587 potently inhibited class I PI3Ks (IC(50) vs. PI3K-alpha = 0.4 nmol/L), PI3K-alpha mutants, and mTOR. PKI-587 inhibited growth of 50 diverse human tumor cell lines at IC(50) values of less than 100 nmol/L. PKI-587 suppressed phosphorylation of PI3K/mTOR effectors (e.g., Akt), and induced apoptosis in human tumor cell lines with elevated PI3K/mTOR signaling. MDA-MB-361 [breast; HER2(+), PIK3CA mutant (E545K)] was particularly sensitive to this effect, with cleaved PARP, an apoptosis marker, induced by 30 nmol/L PKI-587 at 4 hours. In vivo, PKI-587 inhibited tumor growth in breast (MDA-MB-361, BT474), colon (HCT116), lung (H1975), and glioma (U87MG) xenograft models. In MDA-MB-361 tumors, PKI-587 (25 mg/kg, single dose i.v.) suppressed Akt phosphorylation [at threonine(T)308 and serine(S)473] for up to 36 hours, with cleaved PARP (cPARP) evident up to 18 hours. PKI-587 at 25 mg/kg (once weekly) shrank large ( approximately 1,000 mm(3)) MDA-MB-361 tumors and suppressed tumor regrowth. Tumor regression correlated with suppression of phosphorylated Akt in the MDA-MB-361 model. PKI-587 also caused regression in other tumor models, and efficacy was enhanced when given in combination with PD0325901 (MEK 1/2 inhibitor), irinotecan (topoisomerase I inhibitor), or HKI-272 (neratinib, HER2 inhibitor). CONCLUSION: Significant antitumor efficacy and a favorable pharmacokinetic/safety profile justified phase 1 clinical evaluation of PKI-587.
Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.[Pubmed:20166697]
J Med Chem. 2010 Mar 25;53(6):2636-45.
The PI3K/Akt signaling pathway is a key pathway in cell proliferation, growth, survival, protein synthesis, and glucose metabolism. It has been recognized recently that inhibiting this pathway might provide a viable therapy for cancer. A series of bis(morpholino-1,3,5-triazine) derivatives were prepared and optimized to provide the highly efficacious PI3K/mTOR inhibitor 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-y l-1,3,5-triazin-2-yl)phenyl]urea 26 (PKI-587). Compound 26 has shown excellent activity in vitro and in vivo, with antitumor efficacy in both subcutaneous and orthotopic xenograft tumor models when administered intravenously. The structure-activity relationships and the in vitro and in vivo activity of analogues in this series are described.